Earnings call Recursion delivered a strong Q3 2025, ending with $785 million in cash (as of October 9), providing runway through 2027 without additional financing. Management reaffirmed expense ...

Recursion Pharmaceuticals Inc. (RXRX) reported its third-quarter 2025 earnings, revealing a mixed performance with an EPS of -$0.36, slightly surpassing the forecast of -$0.37. However, the company ...

Recursion narrowly beat EPS expectations, signaling effective cost management. Revenue fell short by 69.44%, raising concerns about growth prospects. The company maintains a strong cash position with ...

Hello, everybody, and welcome to Recursion's Third Quarter 2025 (L)earnings Call. My name is Chris Gibson. I'm the Co-Founder and current CEO of Recursion, and I'm so delighted to have you all joining ...

Recursion Pharmaceuticals, Inc. recently held its earnings call, which conveyed an optimistic sentiment. The company is experiencing strong leadership transitions, maintaining a robust financial ...